Get the Stockscreener App
14.04
4.36%
-0.64
After Hours:
13.75
-0.29
-2.07%
Polyrizon Ltd stock is traded at $14.04, with a volume of 120.25K.
It is down -4.36% in the last 24 hours and up +22.30% over the past month.
Polyrizon Ltd is a clinical development stage biotech company specializing in the development of nasal gels to provide preventative treatment to protect against a wide cross-section of viruses, including certain variants of COVID-19 that are also considered to cause more infections and spread faster than the original strain of the virus (the CDC expects that additional variants of the virus will continue to occur), influenza, allergens, and other toxins. The company's technology platforms are Capture & Contain and Trap & Target.
See More
Previous Close:
$14.68
Open:
$16.47
24h Volume:
120.25K
Relative Volume:
2.72
Market Cap:
$29.26M
Revenue:
-
Net Income/Loss:
$-3.34M
P/E Ratio:
-5.201
EPS:
-2.6995
Net Cash Flow:
$-10.54M
1W Performance:
+5.88%
1M Performance:
+22.30%
6M Performance:
-4.42%
1Y Performance:
+51.95%
1-Day Range:
$13.12
$16.47
1-Week Range:
$12.74
$16.47
52-Week Range:
$2.88
$18.20
Polyrizon Ltd Stock (PLRZ) Company Profile
Compare PLRZ vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PLRZ
Polyrizon Ltd
|
14.04 | 30.59M | 0 | -3.34M | -10.54M | -2.6995 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Polyrizon Ltd Stock (PLRZ) Latest News
Polyrizon Ltd (PLRZ) Institutional Confidence - TradingKey
Polyrizon Ltd (PLRZ) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Polyrizon Ltd (PLRZ) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Polyrizon Ltd (PLRZ) Balance Sheet - TradingKey
TradingKey - TradingKey
Polyrizon Ltd (PLRZ) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Polyrizon Ltd. Revenue Breakdown – NASDAQ:PLRZ - TradingView
Polyrizon Shareholders Approve New Executive Compensation Policy on July 13, 2026 - The Globe and Mail
Polyrizon (PLRZ) locks in 3-year executive and director pay policy - Stock Titan
Polyrizon Ltd. (PLRZ) Rises 2.09% as Shares Approach Resistance at $15.38Cash Secured Put - dars.gov.et
Polyrizon Ltd. (PLRZ) Rallies 7.32% to $15.40 — Bulls Test Key ResistanceDouble Top - DonanımHaber
Polyrizon (PLRZ) Holds Steady Near Support as Stock Edges HigherOption Strike Build - dars.gov.et
Polyrizon retains Nasdaq listing following hearings panel - MSN
Polyrizon Clears Key Safety Milestone for NASARIX Allergy Nasal Spray - TipRanks
Polyrizon (PLRZ) clears NASARIX biocompatibility milestone toward first human trial - Stock Titan
Polyrizon Advances on Test Results - Baystreet.ca
Polyrizon shares climb after NASARIX passes key biocompatibility testing (PLRZ) - Yahoo Finance
Polyrizon completes biocompatibility tests for allergy nasal spray - Investing.com
Polyrizon stock rises on biocompatibility test results By Investing.com - Investing.com Nigeria
Polyrizon completes biocompatibility tests for allergy nasal spray By Investing.com - Investing.com Canada
Polyrizon Announces Successful Results for NASARIX™ Biocompatibility Program, Supporting Advancement Towards First in Human Clinical Trial - The Manila Times
Polyrizon Announces Successful Biocompatibility Results for NASARIX Allergy Blocker Nasal Spray - Quiver Quantitative
Polyrizon’s allergy nasal spray clears safety tests, advancing human trial plans - Stock Titan
Polyrizon's NASARIX nasal spray passes biocompa... - Pluang
Polyrizon Wins Central IRB Nod for First NASARIX Allergy Blocker Trial - TipRanks
[6-K] Polyrizon Ltd. Current Report (Foreign Issuer) | PLRZ SEC FilingForm 6-K - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Polyrizon receives IRB approval for nasal spray clinical trial By Investing.com - Investing.com Nigeria
Polyrizon receives IRB approval for nasal spray clinical trial - Investing.com
Polyrizon Receives Central IRB Approval for First Human Clinical Trial of NASARIX Allergy Blocker - Quiver Quantitative
Polyrizon Makes Strong Progress: Receives Central IRB Approval for its Allergy Blocker Clinical Trial - The Manila Times
Polyrizon clears review to start first NASARIX human allergy trial - Stock Titan
Polyrizon gets IRB approval to start clinical t... - Pluang
Polyrizon (PLRZ) Modestly Gains, Testing Key Resistance ZoneLiquidity Sweep - DonanımHaber
Enterprise value to EBIT forward of Polyrizon Ltd. – NASDAQ:PLRZ - TradingView
Enterprise value to revenue forward of Polyrizon Ltd. – NASDAQ:PLRZ - TradingView
Enterprise value to EBITDA forward of Polyrizon Ltd. – NASDAQ:PLRZ - TradingView
Price to sales forward of Polyrizon Ltd. – NASDAQ:PLRZ - TradingView
Polyrizon receives US patent publication notice for nasal drug delivery platform - MSN
Polyrizon Ltd. Ordinary Shares (NASDAQ: PLRZ) Stock Price, News & Analysis - Kalkine
Polyrizon Ltd. (PLRZ) Inches Higher as Stock Approaches Key Resistance LevelCatalyst Driven Stocks - dars.gov.et
Polyrizon Ltd (PLRZ) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Polyrizon Ltd (PLRZ) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Polyrizon Announces U.S. Publication of Mucoadhesive Nasal Drug Delivery Patent - TipRanks
Polyrizon (Nasdaq: PLRZ) details U.S. patent publication for Trap & Target nasal platform - Stock Titan
Polyrizon announces U.S. patent application publication - Investing.com
Polyrizon Receives Notice of U.S. Patent Publication for Mucoadhesive Drug Delivery Platform - The Manila Times
Polyrizon patent published for nasal drug-delivery technology - Stock Titan
Polyrizon's mucoadhesive nasal drug delivery pa... - Pluang
Polyrizon Ltd (PLRZ) Valuation: PE, PB & Fair Value Analysis - TradingKey
Polyrizon Ltd (PLRZ) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Polyrizon Ltd Stock (PLRZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):